Related Experiment Video
Updated: May 19, 2026

Ex Vivo Expansion of Hematopoietic Stem Cells from Human Umbilical Cord Blood-derived CD34+ Cells Using Valproic Acid
Published on: April 11, 2019
Anemia secondary to valproic acid therapy in a 13-year-old boy: a case report
Barbara Kaczorowska-Hac1, Agnieszka Matheisel, Lucyna Maciejka-Kapuscinska
1Department of Pediatrics, Hematology, Oncology, and Endocrinology, Medical University of Gdansk, Gdansk, Poland. bakaczor@gumed.edu.pl.
Introduction:
Valproic acid is a commonly used anti-epileptic drug. Hematological toxicities are among the occasionally observed adverse effects of this medication.
Case Presentation:
We present the case of a 13-year-old Caucasian boy who demonstrated mild anemia 12 months after the introduction of valproic acid therapy. A bone marrow biopsy revealed maturation arrest of proerythroblasts.
Conclusion:
Prompt diagnosis and valproic acid discontinuation resulted in the patient's recovery.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Disorders of Erythrocytes
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Drug Toxicity: Risk factors
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

